Table 2. Clinical Outcomes in the Intention-to-Treat Population.
| Outcome | No. (%) | Rate ratio (95% CI) | P value | |
|---|---|---|---|---|
| Tocilizumab (n = 60) | Standard care (n = 63) | |||
| Primary end point at 14 d | ||||
| Clinical worseninga | 17 (28.3) | 17 (27.0) | 1.05 (0.59-1.86) | .87 |
| Overall events at 14 d | ||||
| Admissions to ICU | 6 (10.0) | 5 (7.9) | 1.26 (0.41-3.91) | |
| Deaths | 1 (1.7) | 1 (1.6) | 1.05 (0.07-16.4) | |
| Discharges | 34 (56.7) | 36 (57.1) | 0.99 (0.73-1.35) | |
| Overall events at 30 d | ||||
| Admissions to ICU | 6 (10.0) | 5 (7.9) | 1.26 (0.41-3.91) | |
| Deaths | 2 (3.3) | 1 (1.6) | 2.10 (0.20-22.6) | |
| Discharges | 54 (90.0) | 58 (92.1) | 0.98 (0.87-1.09) | |
Abbreviations: ICU, intensive care unit; Pao2/Fio2, partial pressure of arterial oxygen/fraction of inspired oxygen.
a
One patient in the standard care group was admitted to the ICU without a Pao2/Fio2 ratio less than 150 mm Hg.